Bangkok, 10 August 2019 – Her Royal Highness Princess Chulabhorn Krom Phra Srisavangavadhana yesterday signed a cooperation agreement, on research and development of biological products, between the Chulabhorn Research Institute, PTT Plc. and the Government Pharmaceutical Organization at Chakri Bongkot Mansion in the capital district of Pathum Thani province.
The agreement is designed to meet Her Royal Highness’s wishes to apply science and technology in improving the people’s quality of life and to provide access to Thai medicine which meets international quality and safety standards at affordable prices. Besides, it will help reduce the volume of and dependence on imported biological products and promote Thailand’s biological product industry and innovation.
The Chulabhorn Research Institute is Thailand’s first and only agency to succeed in developing the biological product called Trastuzumab for treatment of breast cancer. It was the first innovation produced by a Thai researcher without purchases or technology transfers from abroad. The biological product has been registered for clinical use in humans. It can be manufactured at the industrial level, given integrated cooperation under the agreement and financial support from the government.
 |
 |
 |
